Fluoro-substituted inhibitors of D-amino acid oxidase

• US 7,884,124 B2
• Filed: 07/02/2007
• Issued: 02/08/2011
• Est. Priority Date: 06/30/2006
• Status: Active Grant

• Current Assignee: Sepracor Incorporated (Sumitomo Chemical Company Limited)
• Original Assignee: Sepracor Incorporated (Sumitomo Chemical Company Limited)
• Inventors: Spear, Kerry L., Jones, Steven W., Hopkins, Seth C., Heffernan, Michele L. R., Varney, Mark A., Soukri, Mustapha, Foglesong, Robert J.
• Primary Examiner(s): Anderson; Rebecca L
• Application Number:
  US11/772,798
• Publication Number:
  US 20080004327A1
• Time in Patent Office: 1,317 Days
• Field of Search: 548/453, 514/412
• US Class Current: 514/412
• CPC Class Codes: C07D 491/04 Ortho-condensed systems
• CPC Class Codes: C07D 495/04 Ortho-condensed systems

Abstract

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure:

wherein A is NH or S. Q is a member selected from CR¹ and N. X and Y are members independently selected from O, S, CR², N and NH. R¹, R² and R⁴ are members independently selected from H and F, provided that at least one member selected from R¹, R² and R⁴ is F. R⁶ is a member selected from O⁻X⁺ and OH, wherein X⁺ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

Claims

1. A method for treating neuropathic pain, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

2. The method according to claim 1, wherein said compound has a structure according to Formula (II):

3. The method according to claim 2, wherein said compound has a structure according to Formula (III):

4. The method according to claim 2, wherein said compound has a structure according to Formula (IV):

5. The method according to claim 2, wherein R¹ is F.

6. The method according to claim 2, wherein R² is F.

7. The method according to claim 2, wherein R⁴ is F.

8. The method according to claim 1, wherein said neuropathic pain is selected from neuropathic cancer pain, HIV/AIDS induced pain, phantom limb pain, complex regional pain syndrome, chronic migraine, fibromyalgia, lower back pain, causalgia, sensory loss, allodynia, hyperalgesia, hyperpathia, mechanical spinal pain, radiculopathy, myelopathy, and neck pain.

9. The method according to claim 1, wherein said neuropathic pain is selected from central neuropathic pain and peripheral neuropathic pain.

10. The method according to claim 9, wherein said neuropathic pain is central neuropathic pain.

11. The method according to claim 10, wherein said central neuropathic pain is associated with damage to the brain, damage to the spinal cord or a combination thereof.

12. The method according to claim 11, wherein said central neuropathic pain follows stroke.

13. The method according to claim 11, wherein said central neuropathic pain follows spinal cord injury.

14. The method according to claim 11, wherein said central neuropathic pain results from multiple sclerosis.

15. The method according to claim 9, wherein the neuropathic pain is peripheral neuropathic pain.

16. The method according to claim 15, wherein said peripheral neuropathic pain is selected from diabetic peripheral neuropathic pain, post-herpetic neuralgia and trigeminal neuralgia.

17. The method according to claim 16, wherein said peripheral neuropathic pain is diabetic peripheral neuropathic pain.

18. The method according to claim 16, wherein said peripheral neuropathic pain is post-herpetic neuralgia.

19. The method according to claim 16, wherein said peripheral neuropathic pain is trigeminal neuralgia.

20. The method according to claim 1, wherein said compound is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a dosage of from about 1 mg to about 7000 mg of said compound.

21. A method for treating a condition which is a member selected from loss of memory, loss of cognition and a combination thereof, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

22. The method according to claim 21, wherein said compound has a structure according to Formula (II):

23. The method according to claim 22, wherein said compound has a structure according to Formula (III):

24. The method according to claim 22, wherein said compound has a structure according to Formula (IV):

25. The method according to claim 22, wherein R¹ is F.

26. The method according to claim 22, wherein R² is F.

27. The method according to claim 22, wherein R⁴ is F.

28. The method according to claim 21, wherein said condition is associated with Alzheimer'"'"'s disease.

29. The method according to claim 21, wherein said condition is associated with schizophrenia.

30. The method according to claim 21, wherein said compound is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a dosage of from about 1 mg to about 7000 mg of said compound.